Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03006770 is registered in ClinicalTrials.gov with Pluristem Ltd. as lead sponsor.

NCT NCT03006770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03006770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
Lead sponsor
Pluristem Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 22, 2017
Completion date
April 20, 2022
Enrollment
213 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia (cli)